Vugts G, et al. - Considering the increasing trend in neoadjuvant systemic treatment (NST) administration in breast cancer patients, researchers sought for the predictors of tumor response in the breast and axilla. They analyzed all female patients with nonmetastatic, noninflammatory breast cancer receiving NST between 2003-2013 at the Catharina Cancer Institute in Eindhoven, The Netherlands. As per findings, receptor status largely determines the response to NST in the breast and axilla. High pathologic complete response (pCR) rates were noted in HER2-positive and triple-negative tumors. In-breast pCR and HER2-positive disease forecast axillary pCR most relevantly.